VKORC1の変異は,ワルファリン耐性および2型多発凝固因子欠乏症を引き起こす
Simone Rost1, Andreas Fregin, Vytautas Ivaskevicius
1Department of Human Genetics, University of Würzburg, Biozentrum, Am Hubland, 97074 Würzburg, Germany.
Nature
|February 7, 2004
まとめ
研究者らは,血液凝固とワルファリン薬の機能に不可欠なビタミンKエポキシドリドゥクタゼ複合体のサブユニット1 (VKORC1) 遺伝子を特定しました. VKORC1の変異は,出血障害とワーファリン耐性に関連しています.
科学分野:
- バイオケミストリー バイオケミストリー
- 遺伝学 遺伝学とは
- 薬理学 薬理学とは
背景:
- ワルファリンなどのクマリンの誘導体は,血栓栓塞栓症の予防に不可欠です.
- これらの薬は,血液凝固因子合成に不可欠なビタミンKエポキシド還元酵素 (VKOR) 複合体を阻害します.
- VKOR複合体の正確な成分は,VKCFD2とワルファリン耐性におけるその既知の役割にもかかわらず,捉え難いままでした.
研究 の 目的:
- ビタミンKエポキシド還元酵素 (VKOR) 複合体の分子成分を特定するために.
- ビタミンK依存凝固因子2型 (VKCFD2) とワルファリン耐性 (WR) の併合欠乏症の遺伝的根拠を調査する.
主な方法:
- 候補遺伝子を特定するために,3つの種間のリンク分析を使用しました.
- 遺伝子配列解析を行い,罹患した個人や動物モデルにおける突然変異を検出しました.
- 酵素活性を評価するために,遺伝子の過剰発現を含む機能的測定を行った.
主要な成果:
- ビタミンKエポキシド還元酵素複合体のサブユニット1 (VKORC1) をコードする遺伝子を特定し,小さなトランスメブランタンパク質である.
- ヒトのVKCFD2とワルファリン耐性ネズミの両方に関連したVKORC1でミッセンスの変異が見つかりました.
- 野生型VKORC1の過剰発現はVKORの活性を著しく増加させ,ワルファリンによって抑制された.
結論:
- VKORC1は,ビタミンKエポキシド還元酵素複合体の重要な成分である.
- VKORC1の突然変異はVKCFD2の基礎であり,ワルファリン耐性につながる.
- この発見は,凝固障害と薬剤耐性を理解し,潜在的に治療するための分子標的を提供します.
関連する概念動画
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
Pharmacogenetics of Drug Metabolism: Overview
88
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
88
Venous Thrombosis III: Interprofessional Care
453
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
453
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Disorders of Hemostasis
2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K


